Olaparib and enzalutamide synergistically suppress HCC progression via the AR‐mediated miR‐146a‐5p/BRCA1 signaling-Reference-Cited by-同舟云学术

Olaparib and enzalutamide synergistically suppress HCC progression via the AR‐mediated miR‐146a‐5p/BRCA1 signaling

Published:2020-03-05 Issue:4 Volume:34 Page:5877-5891
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Zhao Jie¹²³,Sun Yin³,Lin Hui¹²,Chou Fuju³,Xiao Yao³,Jin Ren'an¹²³,Cai Xiujun¹²,Chang Chawnshang³⁴

Affiliation:

1. Department of General Surgery Innovation Center for Minimally Invasive Technique and Device Sir Run Run Shaw Hospital School of Medicine Zhejiang University Hangzhou China

2. Department of Urology Innovation Center for Minimally Invasive Technique and Device Sir Run Run Shaw Hospital School of Medicine Zhejiang University Hangzhou China

3. George Whipple Lab for Cancer Research Departments of Pathology and Urology and The Wilmot Cancer Institute University of Rochester Medical Center Rochester NY USA

4. Sex Hormone Research Center China Medical University/Hospital Taichung Taiwan

Funder

National Cancer Institute

Taiwan Clinical Oncology Research Foundation

Natural Science Foundation of Zhejiang Province

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.201903045RR

Reference42 articles.